Y-mAbs Therapeutics: cross-border access for the specialty portfolio

Quick orientation

Y-mAbs Therapeutics, Inc. is a US biopharmaceutical company headquartered in Princeton, New Jersey, focused on developing and commercialising antibody-based therapies for pediatric oncology and other cancers. Y-mAbs trades on NASDAQ as YMAB. FDA approval scale is one marketed product, Danyelza, in the ultra-rare and high-mortality pediatric setting of relapsed or refractory high-risk neuroblastoma. The pipeline extends to bispecific antibodies, radioimmunotherapy candidates, and additional GD2-directed programs.

Y-mAbs portfolio in cross-border NPP scope

Danyelza (naxitamab-gqgk) is an FDA-approved humanised monoclonal antibody targeting GD2 (a glycolipid expressed on neuroblastoma cells), indicated in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy (FDA accelerated approval November 2020). Intravenous administration over three consecutive days of each four-week cycle. US list pricing is approximately US$20,000 per vial; total per-cycle cost varies by weight-based dosing and is in the range of US$70,000 to US$110,000 per cycle for an average pediatric patient. The product requires refrigerated cold-chain handling (2 to 8 degrees C).

Y-mAbs pipeline includes omburtamab (radiolabelled antibody for central nervous system neuroblastoma), nivatrotamab (GD2/CD3 bispecific T-cell engager), and earlier-stage candidates. These are investigational and not in NPP scope.

Why patients route through cross-border NPP

High-risk neuroblastoma is a pediatric solid tumor affecting approximately 700 children per year in the United States and an estimated several thousand globally. The high-risk subset has historically poor outcomes, and second-line or maintenance therapy options are limited. Danyelza is one of two FDA-approved GD2-directed antibody therapies (the other being dinutuximab/Unituxin from United Therapeutics), and the differentiated outpatient short-infusion schedule of Danyelza is operationally advantageous in many treatment settings. Outside the United States, Danyelza is not approved by the European Medicines Agency (negative CHMP opinion 2022) and has limited commercial availability in most jurisdictions outside the US.

Patient profile is typically: confirmed high-risk neuroblastoma diagnosis with documented bone or bone marrow disease; documented response of partial, minor, or stable to prior multimodality therapy (typically including induction chemotherapy, surgery, high-dose chemotherapy with autologous stem cell rescue, radiation, and immunotherapy); pediatric oncologist prescription and a treating center with experience in GD2 antibody administration including pain management (the GD2 antibody class causes severe pain on infusion requiring opioid premedication).

Common cross-border destinations

The highest-frequency NPP destinations for Danyelza from US-approved inventory are India, the United Arab Emirates, Saudi Arabia, Turkey, and Egypt. Pediatric oncology centers with neuroblastoma referral concentration in Mumbai, Delhi, Bangalore, Hyderabad, Dubai, Abu Dhabi, Riyadh, Istanbul, and Cairo drive most inbound referrals.

Manufacturer engagement posture

Reserve Meds coordinates Y-mAbs-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with Y-mAbs Therapeutics. Our role is patient-facing coordination on behalf of named individual patients with a verified pediatric oncology prescription. For Y-mAbs medical affairs or commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].

What Reserve Meds provides

For each Danyelza request, Reserve Meds coordinates: prescription verification with the treating pediatric oncologist; documentation review of high-risk neuroblastoma diagnosis and prior multimodality therapy; DSCSA serialized chain-of-custody from Y-mAbs through licensed US wholesalers to the named patient; refrigerated cold-chain shipping (2 to 8 degrees C) with temperature data-loggers; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery. Pediatric neuroblastoma shipments are commonly time-critical and prioritised.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Caregivers of pediatric patients with a confirmed high-risk neuroblastoma diagnosis and a treating-oncologist prescription for Danyelza can begin a request now. Start a request ›

Next step for Y-mAbs teams

Y-mAbs Therapeutics medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].

Reserved for you.